TSR 022

Drug Profile

TSR 022

Alternative Names: TSR-022

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnaptysBio
  • Developer AnaptysBio; TESARO
  • Class Monoclonal antibodies
  • Mechanism of Action HAVCR2 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 Aug 2017 TESARO initiates enrolment in a clinical trial for Solid tumours (Combination therapy) (Parenteral)
  • 27 Apr 2017 TESARO plans a label expansion trial in multiple Cancers (Combination therapy)
  • 08 Mar 2017 TESARO plans a phase I trial for TSR 022 in combination with an anti-PD-1 antibody in mid-2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top